Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Certara launches version 15 of its Simcyp population-based simulator
January 2016
SHARING OPTIONS:

Certara
 
Simcyp Simulator v15 includes a PBPK model for antibody-drug conjugates, a new class of targeted oncology therapies. Its Advanced Dissolution Absorption Metabolism model has also been enhanced to support more physiologically accurate and flexible models of drug disposition in the gut. In addition, the simulator now facilitates modeling biologics in pediatric populations.
 
The Simcyp whole-body simulation methodology can predict the pharmacokinetics and pharmacodynamics of small-molecule and biological medicines using laboratory-derived data. The simulator includes a unique set of genetic, physiological and epidemiological databases that facilitate the simulation of virtual populations of differing demographies and ethnicities.
The majority of the top 40 pharma companies (including all of the top 10) are members of the Simcyp Consortium. The Simcyp Simulator v15 contains several new models and features requested by the Simcyp Consortium.
 
Certara

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2017 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.